首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1479975

2024年全球臨床診斷展望

Global Clinical Diagnostics Outlook, 2024

出版日期: 2024年04月18日 | 出版商:

Frost & Sullivan | 英文 91 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

數位服務和自動化有助於分子診斷和 POCT 產業在 COVID-19 大流行後恢復

隨著 COVID-19 大流行的結束，臨床診斷行業繼續從集中式測試模式過渡到分散式檢查模式，醫療保健提供者將其大部分能力用於預防性醫療保健和精準醫療。從全球來看，2024年預計將是臨床檢測產業獲利的一年，持續成長預計將持續到2029年。主要驅動力將是 POCT 和分子診斷領域，Frost & Sullivan 預測這些領域將在2024年出現更強勁的復甦。

本研究檢視了世界五個地區2024年至2029年的臨床診斷產業趨勢和成長預測。分析創新的體外診斷技術和應用、值得關注的主要供應商以及疫情後現實中的成長機會。還提出了2024年關於產業去中心化趨勢、分子診斷復甦以及自動化解決方案和新數位模型投資增加的五項預測。

預測假設：臨床診斷產業
臨床診斷產業，依細分市場
收益預測，依子區隔
收益預測，依細分市場：強化檢查
收益預測，依細分市場：推薦/週邊設備、分散式檢查
依地區分類的收益預測
依地區分類的收入比例預測
依地區分類的收益預測分析
競爭環境
收益佔有率
收益佔有率分析
競爭矩陣

併購

著名併購
併購：過去的分析

5大預測-2024年

預測1：長期消費行為變化將支持擴大自收集測試範圍
預測2：人手不足將持續推動實驗室自動化實現兩位數成長
預測3：採用 NGS 和專業生物資訊學工具將幫助製藥公司創新
預測4：ctDNA分析將擴大MRD檢測在精準腫瘤學的應用
預測5：與致力於人工智慧的Start-Ups的合作將推動基於人工智慧的數位病理學在臨床領域的採用

行業概況 -2024年

臨床化學/免疫測量-2024

臨床化學和免疫測量產業概況
臨床化學/免疫測量產業：知名企業

分子診斷 -2024

現場檢驗 -2024

組織診斷 -2024

成長機會宇宙

成長機會1：轉向數位診斷服務
成長機會2：擴展到臨床化學和免疫測量的新興市場
成長機會3：遺傳學和心血管疾病分子診斷的預測測試
成長機會4：臨床環境中的分子 POCT
成長機會5：用於免疫測量、STI 和 AMR 應用的多重 POCT

結論

下一步

簡介目錄

Product Code: KA03-55

Driven by Digital Services and Automation, the Molecular Diagnostics and POCT Sectors Rebound after the COVID-19 Pandemic

With the end of the COVID-19 pandemic, healthcare providers have been directing most of their capabilities toward preventive healthcare and precision medicine, as the clinical diagnostics industry continues its transition from a centralized to a decentralized testing model. Globally, 2024 is set to be a profitable year for the industry, which will likely witness sustained growth through to 2029. The main growth drivers will be the point-of-care testing (POCT) and molecular diagnostics sectors, which Frost & Sullivan expects to rebound even more strongly in 2024.

This study examines clinical diagnostics industry trends and growth projections from 2024 to 2029 across five global regions. It analyzes innovative in vitro diagnostics technologies and applications, major vendors to watch, and growth opportunities in the post-pandemic reality. The research also provides the top 5 predictions for 2024 related to the industry's decentralization trend, the recovery of molecular diagnostics, and the higher investments in automated solutions and novel digital models.

Analysis Highlights

Analysis Highlights
The 2023 Clinical Diagnostics Industry: Forecast vs. Actual
Top Clinical Diagnostics Predictions for 2024

Strategic Imperatives

Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Clinical Diagnostics Industry
Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Environment

Segmentation
Growth Environment

Macroeconomic Factors

Top 10 Trends for 2024
Top 10 Growth Opportunities
1. Global GDP Growth-Mild Global Growth Slowdown from 3.0% in 2023 to 2.6% in 2024 as Key Economies Lose Growth Momentum
2. Inflation and Interest Rates-Headline Inflation to Continue to Decline; H2 2024 Shift Toward Rate Cuts for Advanced Economies
3. Currency Trajectory-Dollar to Remain Strong in H1 2024; Emerging Market Currencies to Get Boost from Q3 2024 Onwards
4. Labor Market-Moderate Unemployment Uptick; Positive Expectations Over Market Sentiment to Support Labor Hoarding
5. Oil Markets-Q1 OPEC+ Oil Production Cuts; Non-OPEC Production to Rise
6. Critical Minerals Supplies-Need for Economic Resiliency to Bolster Cross-border and Cross-industry Partnerships
7. North America-Economic Slowdown Amidst Discretionary Spending Pullback and Elevated Interest Rates
8. Western Europe-Moderate Growth Pick-up as Inflation Headwinds Ease Gradually; Rebuilding Fiscal Buffers to Take Precedence
9. Middle East-Non-oil Growth Driven by Economic Diversification to Limit Pullback Caused by a Slowdown in Global Oil Markets
10. Asia-Emerging Economies to Drive Growth Momentum; Fiscal Measures to Support Chinese Economic Recovery

Revenue Trends-2024

Forecast Assumptions: Clinical Diagnostics Industry
Clinical Diagnostics Industry by Segment
Revenue Forecast by Subsegment
Revenue Forecast by Segment: Centralized Testing
Revenue Forecast by Segment: Referral & Peripheral and Decentralized Testing
Revenue Forecast by Region
Percent Revenue Forecast by Region
Revenue Forecast Analysis by Region
Competitive Environment
Revenue Share
Revenue Share Analysis
Competitor Matrix

Mergers and Acquisitions

Notable M&As in 2023
M&As: Historical Analytics

Top 5 Predictions-2024

Prediction 1: Long-term Change in Consumer Behavior Supports Expansion into Self-collection Testing
Prediction 2: Staff Shortages Continue to Drive Double-digit Lab Automation Growth Rate
Prediction 3: Adoption of NGS and Specialized Bioinformatics Tools Will Support Pharma Innovation
Prediction 4: ctDNA Analysis Will Expand the Application of MRD Testing for Precision Oncology
Prediction 5: Partnerships with AI-focused Start-ups to Promote Adoption of AI-based Digital Pathology in Clinical Segments

Industry Snapshot-2024

2024 Industry Snapshot

Clinical Chemistry and Immunoassays-2024

Clinical Chemistry and Immunoassays Industry Snapshot
Clinical Chemistry and Immunoassays Industry: Companies to Watch

Molecular Diagnostics-2024

Molecular Diagnostics Industry Snapshot
Molecular Diagnostics Industry: Companies to Watch

POCT-2024

POCT Industry Snapshot
POCT Industry: Companies to Watch

Tissue Diagnostics-2024

Tissue Diagnostics Industry Snapshot
Tissue Diagnostics Industry: Companies to Watch

Growth Opportunity Universe

Growth Opportunity 1: Shift toward Digital Diagnostics Services
Growth Opportunity 2: Expansion of Clinical Chemistry and Immunoassays to Emerging Markets
Growth Opportunity 3: Predictive Testing in Molecular Diagnostics for Genetics and Cardiovascular Diseases
Growth Opportunity 4: Molecular POCT in Clinical Settings
Growth Opportunity 5: Multiplex POCT for Immunoassay, STI, and AMR Applications